Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
FPH1 was suggested to be supplemented into the culture medium on day 1 and 5 at a concentration of 15-20 μM to induce functional proliferation of primary human hepatocytes in vitro
PubMed Central PMCID: PMC2797793
which is a specific substrate of CPP32-like caspases
Shaburishvili T
100 μM) shows inhibitroy effects on NO and PGE2 production in LPS-stimulated synovial fibroblasts
TraMetinib - CAS# 871700-17-3 0201 FPH1 was suggested to beTrametinib, also known as GSK1120212, CAS No. 871700 17 3, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in